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Forkhead box (Fox)/winged-helix transcription factors regulate multiple aspects of immune responsiveness and Foxp3
is recognized as an essential functional marker of regulatory T cells. Herein we describe downstream signaling
pathways targeted by Foxp3 that may negatively impact retroviral pathogenesis. Overexpression of Foxp3 in HEK 293T
and purified CD4
þ T cells resulted in a dose-dependent and time-dependent decrease in basal levels of nuclear factor-
jB (NF-jB) activation. Deletion of the carboxyl-terminal forkhead (FKH) domain, critical for nuclear localization and
DNA-binding activity, abrogated the ability of Foxp3 to suppress NF-jB activity in HEK 293T cells, but not in Jurkat or
primary human CD4
þ T cells. We further demonstrate that Foxp3 suppressed the transcription of two human retroviral
promoters (HIV-1 and human T cell lymphotropic virus type I [HTLV-I]) utilizing NF-jB-dependent and NF-jB-
independent mechanisms. Examination of the latter identified the cAMP-responsive element binding protein (CREB)
pathway as a target of Foxp3. Finally, comparison of the percent Foxp3
þCD4
þCD25
þ T cells to the HTLV-I proviral load
in HTLV-I-infected asymptomatic carriers and patients with HTLV-I-associated myelopathy/tropical spastic paraparesis
suggested that high Foxp3 expression is associated with low proviral load and absence of disease. These results
suggest an expanded role for Foxp3 in regulating NF-jB- and CREB-dependent cellular and viral gene expression.
Citation: Grant C, Oh U, Fugo K, Takenouchi N, Griffith C, et al. (2006) Foxp3 represses retroviral transcription by targeting both NF-jB and CREB pathways. PLoS Pathog 2(4):
e33. DOI: 10.1371/journal.ppat.0020033
Introduction
Immunological tolerance to self-antigens is the result of the
deletion of self-reactive T lymphocytes in the thymus (central
tolerance)andsuppressionoftheactivationofpotentiallyself-
reactiveTlymphocytes intheperiphery(peripheraltolerance)
[1]. Suppression of pathogenic T cell responses is mediated by
naturally arising CD4
þCD25
þ T regulatory cells (Tregs) [2,3].
Deﬁciencies in Treg development and function have been
linked to the severe autoimmune disorder known as immune
dysregulation, polyendocrinopathy, enteropathy, X-linked
syndrome (IPEX) [4]. In addition, recent studies have provided
strong evidence that dysregulation of Treg development and/
or function may be a signiﬁcant factor in the pathogenesis of
several autoimmune disorders (e.g., multiple sclerosis [5],
myasthenia gravis [6], and type 1 diabetes [7]) and virus-
induced immunologic disorders (e.g., human T lymphotropic
virus type I [HTLV-I]-associated myelopathy/tropical spastic
paraparesis [HAM/TSP], and HIV-induced AIDS [8–10]).
The transcription factor Foxp3 is a 431-amino acid (48-
kDa) protein expressed at very high levels in CD4
þCD25
hi T
cells and has previously been shown to be absolutely critical
for Treg development and function [11–14]. Foxp3 contains a
proline-rich amino-terminal domain reported to function as
a nuclear factor of activated T cells (NF-AT) and nuclear
factor-jB (NF-jB) binding domain, a central region contain-
ing a zinc ﬁnger and leucine zipper potentially important for
protein-protein interactions, and a carboxyl-terminal fork-
head (FKH) domain required for nuclear localization and
DNA-binding activity [14–16]. Functional inactivation of
Foxp3 by genetic mutations affecting the Foxp3 coding
region, as demonstrated in IPEX, or repression of Foxp3
expression by the HTLV-I-encoded transactivator protein
Tax, as recently reported in patients with HAM/TSP, results
in loss of regulatory activity in CD4
þCD25
hi T cells [4,8,17].
Although it is clear that Foxp3 regulates T cell proliferation
and cytokine production, very little is known concerning the
molecular mechanisms of Foxp3 function.
The ﬁrst evidence to indicate how Foxp3 promotes the
development and function of regulatory T cells came from a
report by Ziegler and colleagues [16], which suggested that
Foxp3 could inhibit transcriptional activation by physically
interacting with forkhead binding sites located immediately
adjacent to critical cis-acting NF-AT binding sites found in
various cytokine promoters (e.g., IL-2 promoter). That study
also demonstrated that Foxp3 could repress activation of a
synthetic reporter vector containing an SV40 promoter and
three tandem copies of a forkhead binding site. These results
provided additional evidence suggesting that Foxp3 tran-
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sequence-speciﬁc manner to promoters containing forkhead
binding sites. A recent study by Bettelli and colleagues [15]
further demonstrated that Foxp3 could inhibit NF-AT as well
as NF-jB activation, although the mechanism of suppression
was shown to involve direct protein-protein interactions
between NF-AT or NF-jB and Foxp3 rather than binding of
Foxp3 to promoter elements adjacent to cis-acting NF-AT or
NF-jB sites. Collectively, these data suggested that Foxp3 may
function as a transcriptional repressor, potentially through
the formation of both DNA-protein and protein-protein
interactions.
In the present study, we expanded upon these observations
by deﬁning additional requirements of Foxp3-mediated
repression of NF-jB activation, and investigated whether
Foxp3 could target additional signaling pathways by examin-
ing transcriptional activation of NF-jB-dependent and NF-
jB-independent retroviral pathogens. The characterization
of the molecular targets of Foxp3 and the mechanism(s)
utilized by Foxp3 to support Treg development and function
will aid in our understanding of the role Tregs play in the
pathogenesis of human autoimmune disease.
Results
Foxp3 Suppresses NF-jB Dependent Transcriptional
Activation
To ascertain the molecular mechanisms by which Foxp3
functions to promote the regulatory function of CD4
þCD25
hi
T cells, we ﬁrst conﬁrmed the function of Foxp3 as a
repressor of activation of NF-jB, previously implicated as a
target of other forkhead/winged-helix family transcription
factors (e.g., Foxj1 and Foxo3a) [19,20]. We analyzed the effect
of Foxp3 overexpression on NF-jB activation in HEK 293T
cells in dose-response and time course analyses. Transfection
of HEK 293T cells with an NF-jB luciferase reporter vector in
the presence or absence of increasing concentrations of a
Foxp3 expression vector or a control vector (enhanced green
ﬂuorescent protein [EGFP]) was performed, and cells were
harvested after 24 h to assay for luciferase activity and Foxp3
mRNA expression. Results indicated that as the concentra-
tion of Foxp3 transfected into cells increases (from 50 to
2,400 ng), the level of NF-jB activation decreases propor-
tionally (Figure 1A). Foxp3 mRNA was also assayed to
monitor activity of the Foxp3 expression vector (Figure 1B).
Since NF-jB activation was partially affected by transfection
of high concentrations of the control vector, we determined
the fold inhibition of NF-jB activation by Foxp3 compared to
the control vector at each concentration (Figure 1A). Fold
inhibition of NF-jB activation was directly proportional to
the level of Foxp3 mRNA expression detected by real-time
RT-PCR. To determine the level of Foxp3-mediated suppres-
sion of NF-jB activation over time, HEK 293T cells were
transfected with an NF-jB luciferase reporter vector and an
expression vector encoding Foxp3 or EGFP (control vector)
and harvested over 4 d. As shown in Figure 1C, NF-jB
activation was suppressed by overexpression of Foxp3 at all
time points. Extending these results from established, in vitro
HEK cell lines to primary human lymphocytes, overexpres-
sion of Foxp3 in puriﬁed CD4
þ T cells from three healthy
donors also down-regulated the steady-state level of NF-jB
activation (Figure 1D). These results recapitulate those from
Bettelli and colleagues [15] demonstrating that Foxp3
functions, in part, to block NF-jB-dependent transcription
in human cell lines as well as in primary human CD4
þ T cells.
The Carboxyl-Terminal FKH Domain Is Not Required for
Suppression of NF-jB Activation in T Cells
To deﬁne the requirements of Foxp3 with respect to
inhibition of NF-jB-dependent transcription, we utilized a
mutant of Foxp3 lacking the FKH domain (Figure 2A) [16],
similar to the scurfy mutant Foxp3 of mice, and a mutant
Foxp3 protein from a patient with IPEX [4,11,14,17]. Unlike
full-length Foxp3, which localizes almost exclusively to the
nucleus and can bind in a sequence-speciﬁc manner to
forkhead binding sites, the DFKH mutant fails to localize to
the nucleus and thus cannot interact with promoter elements
or nuclear proteins [16]. Therefore, we utilized the DFKH
mutant to determine whether nuclear localization (or other
function associated with the FKH domain) of Foxp3 was a
prerequisite for inhibition of NF-jB activation. Although
Foxp3 interaction with NF-jB presumably takes place in the
nucleus, it may also be possible for a cytoplasmic Foxp3
protein to bind to NF-jB in the cytoplasm and prevent
localization to the nucleus following an activation stimulus.
Overexpression of full-length Foxp3, but not of DFKH, was
able to suppress activation of a cotransfected NF-jB reporter
vector in HEK 293T cells (Figure 2B). Both Foxp3 and DFKH
were expressed at very high levels following transfection as
detected by real-time RT-PCR (unpublished data). These data
appear to suggest that the carboxyl-terminal FKH domain is
critically important for Foxp3 to down-regulate NF-jB-
dependent transcription. However, NF-jB activation was
blocked to a similar extent by both full-length Foxp3 and
DFKH in Jurkat T cells (Figure 2C) and primary human CD4
þ
T cells (Figure 2D). Western blot analysis of NF-jB p65
expression demonstrated that Foxp3 and DFKH does not
block NF-jB activation at the level of p65 protein expression
(Figure 2E). These results are very interesting with respect to
Foxp3 function, because they suggest that the carboxyl-
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Synopsis
Over the past several years, mounting evidence has shown that
immune tolerance in healthy individuals can be maintained by a
population of T lymphocytes known as regulatory T cells (Tregs). As
a component of this system, a protein known as Foxp3 has been
shown to be absolutely required for the development and function
of Tregs. While Foxp3 plays an important role in maintaining
immune tolerance by blocking T cell proliferation and production of
inflammatory proteins known as cytokines, little is known about the
molecular mechanisms that are used by Foxp3 to accomplish these
events. The present study expands our understanding of how Foxp3
maintains a check on inappropriate immune responses by
demonstrating that Foxp3 can block activation of key inducible
proteins such as nuclear factor jB (NF-jB) and cAMP-responsive
element binding protein (CREB). Since NF-jB and CREB are integrally
involved in controlling cell cycle progression, inflammatory cytokine
production, and the replication of numerous viruses at the level of
transcription, understanding the mechanisms by which Foxp3
functions to regulate cellular and viral gene expression may aid in
the discovery of therapeutic approaches designed to rescue the
expression and/or function of Foxp3, which have been found to be
deficient in several autoimmune diseases and virus-induced
disorders.terminal FKH domain, and possibly nuclear localization, are
dispensable for Foxp3 function in T cell populations.
Alternative interpretations may include the possibility that
the localization of DFKH differ between epithelial cells and T
cells. In either case, these results suggest a cell type-speciﬁc
mechanism of action for this Foxp3 mutant.
Foxp3 Suppresses HIV-1 Gene Expression in Part through
Blocking Activation of NF-jB
If Foxp3 functions as a repressor of NF-jB-dependent gene
expression, then we hypothesized that Foxp3 overexpression
could selectively down-regulate transcription from pro-
moters previously shown to be responsive to NF-jB. To
address this question, we examined the transcriptional
activation of the HIV-1 LTR, which contains two tandem
cis-acting NF-jB binding sites located between positions 102
and  81 with respect to the transcription initiation site [21].
NF-jB plays a crucial role in regulating gene expression
directed from the HIV-1 LTR in CD4
þ T cells [21]. Over-
expression of full-length Foxp3, but not DFKH, in HEK 293T
cells was able to inhibit basal activation of the HIV-1 LTR
(Figure 3A), similar to what was previously demonstrated with
the synthetic NF-jB reporter vector (Figure 2B). Further-
more, HIV-1 LTR activation was suppressed by full-length
Foxp3 and DFKH in Jurkat T cells (Figure 3B). To
demonstrate that Foxp3-mediated HIV-1 LTR repression
was associated with interactions with NF-jB bound to the
HIV-1 LTR, we compared basal activation of the HIV-1 LTR
or an identical HIV-1 LTR lacking the NF-jB sites located
between  102 and  81 (HIV-1 D-jB LTR) (Figure 3C). This
mutant HIV-1 LTR construct exhibited reduced levels of
transcription compared to the parental HIV-1 LTR in
puriﬁed healthy donor CD4
þ T cells (unpublished data).
However, directly comparing the effect of Foxp3 over-
expression on the activation of these two viral promoters
demonstrated that Foxp3 was more capable of suppressing
transcriptional activation of the HIV-1 LTR (Figure 3D)
compared to the mutated HIV-1 LTR (Figure 3E). These
results suggest that Foxp3 down-regulation of HIV-1 LTR
activation was mediated at least in part by cis-acting NF-jB
binding sites. Residual levels of inhibition of the HIV-1 D-jB
Figure 1. Foxp3 Suppresses NF-jB-Dependent Transcription
(A and B) HEK 293T cells (5 3 10
5) were seeded into six-well plates 1 d prior to transfection with an NF-jB luciferase reporter vector (200 ng) in the
presence or absence of indicated concentrations of a Foxp3 expression vector or a control vector and internal reference plasmid (pGL4-TKhRluc2; 50
ng). Cells were harvested 24 h posttransfection and analyzed for luciferase activity (A) and Foxp3 mRNA expression (B).
(C) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with an NF-jB luciferase reporter vector (200 ng) in the presence or
absence of a Foxp3 expression vector or a control vector (1,500 ng) and internal reference plasmid (pGL4-TKhRluc2; 50 ng). Cells were harvested at 24,
48, 72, and 96 h posttransfection and analyzed for luciferase activity.
(D) CD4
þ T cells (2 3 10
6) from three healthy donors were nucleofected with an NF-jB luciferase reporter vector (1,000 ng) and Foxp3 or control
expression vectors (2,000 ng) and internal reference plasmid (1,000 ng). Cells were harvested 24 h posttransfection and analyzed for luciferase activity.
Relative luciferase activity shown in A, C, and D was normalized to the internal reference control.
DOI: 10.1371/journal.ppat.0020033.g001
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upstream of the NF-jB sites within the HIV-1 LTR [22,23].
The Transactivation Functions of HTLV-I Tax Are
Suppressed by Foxp3
Previous studies by Bettelli and colleagues have demon-
strated that Foxp3 can repress both the basal levels of NF-jB
activation as well as tumor necrosis factor-a-stimulated NF-jB
activation [15]. Our next step was to determine whether Foxp3
could also suppress the activation of NF-jB caused by a strong
viral transactivator protein. HTLV-I encodes a multifunc-
tional transactivator protein, Tax, capable of activating both
the NF-jB and CREB pathways [24–29]. Since the HTLV-I Tax
protein can function at multiple levels in both the cytoplasm
and the nucleus to stimulate activation of NF-jB [28,29], we
hypothesized that overexpression of Foxp3 may interfere with
this process. However, since Tax-dependent HTLV-I gene
expression is independent of NF-jB [18], we also hypothesized
that Foxp3 would not affect Tax-dependent activation of the
HTLV-I LTR. To test these hypotheses, we overexpressed
HTLV-I Tax, full-length Foxp3, and/or DFKH in HEK 293T
cells cotransfected with an HTLV-I LTR or NF-jB reporter
vector. As shown in Figure 4A, HTLV-I Tax strongly up-
regulated NF-jB-dependent transcriptional activation (;60-
fold). Interestingly, overexpression of Foxp3, but not DFKH,
suppressed Tax-mediated activation of NF-jB-dependent
transcription. These observations further suggest that the
carboxyl-terminal FKH domain is required for inhibiting
activation of NF-jB in the presence of Tax in HEK 293T cells,
strikingly similar to the requirements of Foxp3 inhibition of
basal NF-jB activation shown in Figure 2B. Transactivation of
the HTLV-I LTR was stimulated about 55-fold by over-
expression of Tax (Figure 4B), while transfection of Foxp3
suppressed Tax-dependent HTLV-I LTR activation, although
HTLV-I LTR activation in the presence or absence of Tax is
independent of NF-jB or NF-AT (another transcriptional
activator known to interact with Foxp3). Furthermore, over-
expression of DFKH also led to suppression of HTLV-I
Figure 2. FKH Domain of Foxp3 Is Required to Inhibit NF-jB Activation in HEK 293T Cells but Not CD4
þ T Cells
(A) Schematic representation of human Foxp3, including proline-rich (P-P-P), zinc finger (ZNF), leucine zipper (ZIP), and forkhead (FKH) domains.
Mutations within the Foxp3 gene associated with IPEX have been previously described [4,14,43]. The FKH domain contains a nuclear localization signal
(NLS), which is required for Foxp3 expression in the nucleus.
(B and C) HEK 293T cells (5310
5) (B) were seeded into six-well plates 1 d prior to transfection or Jurkat T cells (1310
6) (C) were seeded into six-well
plates on the day of transfection with an NF-jB luciferase reporter vector (200 ng) in the presence or absence of a Foxp3, DFKH, or control expression
vector (1,000 ng) and internal reference plasmid (pGL4-TKhRluc2; 50 ng). Cells were harvested at 24 h posttransfection and analyzed for luciferase
activity. Relative luciferase activity was normalized to the internal reference control.
(D) CD4
þ T cells (2 3 10
6) from healthy donors were nucleofected with an NF-jB reporter plasmid (2,000 ng), together with either a Foxp3, DFKH, or
control expression vector (2,000 ng), and an internal reference plasmid (1,000 ng). Cells were harvested 24 h posttransfection and analyzed for luciferase
activity. Relative luciferase activity was normalized to the internal reference control. Results from one healthy donor are shown.
(E) Foxp3, DFKH, and NF-jB p65 expression in whole-cell extracts (20 lg) derived from HEK 293T cells transfected with a control expression vector
(EGFP), Foxp3, or DFKH expression vectors were analyzed by Western blot analysis. b-actin expression was analyzed as a loading control.
DOI: 10.1371/journal.ppat.0020033.g002
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(Figure 4B). The suppressive effects shown inFigure 4A and 4B
were not the result of Foxp3 down-regulating the expression
of the transfected Tax plasmid as determined by real-time RT-
PCR (Figure 4C). These results strongly suggest that Foxp3
interacts with transcriptional regulators in addition to NF-jB
and NF-AT, and that the carboxyl-terminal FKH domain, and
therefore localization to the nucleus, are not required for
inhibition of Tax-mediated HTLV-I LTR activation (even in
HEK 293T cells).
To determine whether Foxp3 inhibited the transactivation
functions of Tax by directly associating with this viral protein,
we generated an expression vector in which HTLV-I Tax was
fused in-frame to the carboxyl terminus of the Gal4 DNA-
binding domain (Gal4-BD). This Gal4-BD-Tax fusion protein
activated transcription of a synthetic promoter containing
ﬁve Gal4 binding sites, while Gal4-BD was insufﬁcient to
stimulate transcription by itself (Figure 4D). Transactivation
of the Gal4-resposive promoter by Gal4-BD-Tax remained
relatively unaffected by overexpression of either EGFP
(control), Foxp3, or DFKH, suggesting that Foxp3 does not
repress Tax transactivation by directly interfacing with the
HTLV-I Tax protein. To conﬁrm that Foxp3 had a direct
effect on HTLV-I replication, we transfected HEK 293T cells
with a well-characterized HTLV-I infectious molecular clone
(termed ACH) [30] in the presence of full-length Foxp3,
DFKH, or control vector. ACH has been previously shown to
direct the expression of viral antigens, produce infectious
virus, and transform CD4
þ T cells both in vitro and in vivo
[31,32]. After 24 h, the amount of viral antigen expression, in
this case Tax mRNA, was detected by a sensitive real-time RT-
PCR assay. As illustrated in Figure 5, the level of Tax mRNA
synthesized from ACH was down-regulated in the presence of
Foxp3 compared to the level produced in the presence of the
control vector. DFKH did not have a discernable affect on
Tax expression. These data indicate that Foxp3 is capable of
repressing the expression of Tax from an infectious HTLV-I
molecular clone.
Increased Foxp3 Protein Expression Is Associated with
Low HTLV-I Proviral Load
Since Foxp3 is expressed almost exclusively within
CD4
þCD25
þ T cells, a major viral reservoir for HTLV-I [33],
it was important to determine whether there was an
association between Foxp3 and HTLV-I replication in
infected patients. We therefore quantitated the Foxp3
protein expression in CD4
þCD25
þ T cells by ﬂow cytometry
and the HTLV-I proviral load (a surrogate marker of viral
Figure 3. Foxp3 Inhibits Basal Activation of the HIV-1 LTR
(A and B) HEK 293T cells (5310
5) (A) were seeded into six-well plates 1 d prior to transfection or Jurkat T cells (1310
6) (B) were seeded into six-well
plates on the day of transfection with an HIV-1 LTR luciferase reporter vector (200 ng) in the presence or absence of a Foxp3, DFKH, or control
expression vector (1,000 ng) and internal reference plasmid (pGL4-TKhRluc2; 50 ng). Cells were harvested at 24 h posttransfection and analyzed for
luciferase activity.
(C) Schematic representation of HIV-1 LTR luciferase reporter constructs pHIV-1 LTR-luc and pHIV-1 D-jB LTR-luc.
(D and E) CD4
þT cells (2310
6) from two healthy donors were nucleofected with either parental HIV-1 LTR (D) or HIV-1 LTR lacking NF-jB binding sites
(at 102 to 81) (E) (1,000 ng), Foxp3 or control expression vectors (2,000 ng), and an internal reference plasmid (1,000 ng). Cells were harvested 24 h
posttransfection and analyzed for luciferase activity. Relative luciferase activity shown in A, B, D, and E was normalized to the internal reference control.
DOI: 10.1371/journal.ppat.0020033.g003
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TSP and eight asymptomatic carriers (ACs). The data from
this analysis is summarized in Table 1. As expected, patients
with HAM/TSP exhibited signiﬁcantly higher proviral loads
(indicated as HTLV-I proviral DNA copies/100 cells) (34.68 6
23.19) compared to ACs (4.75 6 5.47) (p ¼ 0.0008). The
percentage of Foxp3
þ cells within the CD4
þCD25
þ T cell
population was signiﬁcantly greater in ACs (43.23 6 12.95)
than in HAM/TSP patients (18.59 6 5.77) (p ¼ 0.0033). These
data suggest that high levels of Foxp3 protein expression are
associated with reduced HTLV-I replication in vivo. They also
support our recent reports that high proviral loads, which
have been shown to correlate with high Tax mRNA in HTLV-
I-infected patients, are associated with reduced Foxp3
expression [8,34].
CREB Is a Target for Transcriptional Repression by Foxp3
Although Foxp3 could down-regulate Tax-dependent
transactivation of the HTLV-I LTR (Figure 4B) and inhibit
Tax expression from an infectious molecular clone (Figure 5),
Foxp3 failed to modulate Tax function in the absence of the
viral promoter (Figure 4D). These results led us to hypothe-
size that Foxp3 acts on HTLV-I gene expression by interact-
ing with proteins important for driving HTLV-I LTR activity
in vivo. Previous studies have demonstrated that the Tax-
responsive elements within the HTLV-I LTR play a crucial
role in driving Tax-mediated transactivation of the HTLV-I
LTR [18]. The Tax-responsive elements have been shown to
resemble CREB binding sites, bind CREB in vitro and in vivo,
and facilitate HTLV-I LTR activation both in the presence
and in the absence of Tax [35,36]. Ching and colleagues [18]
demonstrated that addition of a dominant-negative CREB
expression vector resulted in nearly complete inhibition of
Tax-mediated activation of the HTLV-I LTR, while blocking
NF-jB activation by addition of a dominant-negative IKKb
expression vector had no effect on Tax transactivation of the
HTLV-I LTR. Therefore, we hypothesized that Foxp3 may
inhibit Tax transactivation of the HTLV-I LTR via disruption
of the CREB signaling pathway. To test this possibility, HEK
293T cells were transfected with an HTLV-I LTR or synthetic
CREB reporter vector along with a control expression vector
(EGFP) or expression vectors encoding Foxp3 or DFKH. As
shown in Figure 6A, Foxp3 down-regulated basal activation of
the HTLV-I LTR and transcription of a synthetic CREB
reporter vector, suggesting that Foxp3 down-regulates
HTLV-I LTR activation by targeting the CREB pathway.
Deletion of the FKH domain of Foxp3 dampened the
suppressive effect of Foxp3, but did not completely abrogate
Figure 4. Transactivation Functions of HTLV-I Tax Are Blocked by Overexpression of Foxp3
(A and B) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with NF-jB (A) or HTLV-I LTR (B) luciferase reporter vectors
(200 ng) in the presence or absence of an HTLV-I Tax, Foxp3, DFKH, or control expression vector (500 ng) and internal reference plasmid (pGL4-
TKhRluc2; 50 ng). Cells were harvested at 24 h posttransfection and analyzed for luciferase activity. Relative luciferase activity was normalized to the
internal reference control.
(C) Expression of HTLV-I Tax in (A) and (B) was measured by quantitative RT-PCR (TaqMan) to demonstrate that Foxp3 did not suppress Tax
transactivation of NF-jB and the HTLV-I LTR by down-regulating the expression of Tax.
(D) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with a Gal4 luciferase reporter vector (200 ng) in the presence or
absence of a Gal4-BD or Gal4-BD-Tax expression vector (500 ng), Foxp3, DFKH, or control expression vector (500 ng) and internal reference plasmid
(pGL4-TKhRluc2; 50 ng). Cells were harvested at 24 h posttransfection and analyzed for luciferase activity. Relative luciferase activity was normalized to
the internal reference control.
DOI: 10.1371/journal.ppat.0020033.g004
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HEK 293T cells. Like NF-jB activation, CREB transcriptional
activation was also suppressed by expression of Foxp3, and to
a similar extent DFKH, in healthy donor CD4
þ T cells (Figure
6B). Similarly, Foxp3 and DFKH also repressed basal HTLV-I
LTR activation in primary human CD4
þ T cells (Figure 6C).
To our knowledge, this is the ﬁrst evidence implicating CREB
as a molecular target of Foxp3. As observed with NF-jB
activation, DFKH was a more potent inhibitor of CREB
activation in CD4
þ T cells than in HEK 293T cells, further
indicating that a cell type-speciﬁc mechanism of action may
govern the function of this Foxp3 mutant.
To determine whether Foxp3 functioned by directly
signaling through CREB, we utilized expression vectors
encoding CREB-1 or c-Jun (a member of the activator protein
1 family of transcription factors) fused in-frame to the Gal4-
BD (Gal4-BD-CREB-1 and Gal4-BD-c-Jun). As shown in
Figure 6D, activation of a Gal4-responsive reporter vector
by Gal4-BD-CREB-1 was down-regulated by Foxp3 compared
to control vector (EGFP), indicating that Foxp3 functions by
directly or indirectly interacting with CREB-1. However,
Foxp3 failed to markedly affect transcriptional activation of
Gal4-BD-c-Jun (c-Jun has also been demonstrated to bind to
the HTLV-I LTR) and Gal4-BD-Tax (see Figure 5). Impor-
tantly, the mechanism of Foxp3-mediated inhibition of
CREB-dependent transcription was not due to a block in
CREB-1 protein expression, as determined by Western blot
analysis (Figure 6E). Although these results demonstrate that
Foxp3 functions as a co-repressor of CREB activation (in
addition to NF-jB and NF-AT), we were unable to detect a
direct physical interaction between CREB-1 and Foxp3 by
coimmunoprecipitation or mammalian two-hybrid analysis
(unpublished data). Therefore, our data suggest that Foxp3
may interfere with CREB signaling at an upstream event, such
as phosphorylation of CREB or recruitment/function of
coactivator proteins CREB-binding protein (CBP)/p300.
Foxp3 Antagonizes CREB Transcriptional Activation by
Disrupting Coactivator Recruitment
Stimulation of CREB-dependent transcription by reagents
that activate adenylate cyclase and increase cAMP levels (e.g.,
forskolin) increase the transactivation potential of CREB
through phosphorylation of serine 133 by protein kinase A,
which permits binding and recruitment of coactivators CBP/
p300 to the promoter [37,38]. Phosphorylation of serine 133
does not, however, affect the DNA-binding activity of CREB
in most cases [39–41]. Addition of forskolin to HEK 293T cells
stimulated activation of a CREB reporter vector about 65 fold
(Figure 7A). Overexpression of Foxp3 was capable of down-
regulating forskolin-induced CREB transcriptional activa-
tion. The functional interaction between Foxp3 and CREB
did not affect the DNA-binding activity of CREB-1, but did
show a modest decrease in activating transcription factor 2
(ATF-2) DNA-binding activity in the presence of forskolin as
determined by transcription factor ELISA (Figure 7B).
While Foxp3 has been shown to bind to and repress
activation of both NF-jB and NF-AT, exactly how Foxp3
functions to bring about this affect has not been elucidated.
To determine how Foxp3 blocks CREB-dependent tran-
scription, we examined whether Foxp3 was capable of (1)
disrupting the recruitment of coactivator proteins and/or (2)
preventing phosphorylation of CREB at serine 133 (which is a
prerequisite for coactivator recruitment). Since both of these
events are required for CREB-dependent gene expression, we
hypothesized that Foxp3 may affect CREB activation at both
Table 1. Expression of Foxp3 in CD4
þCD25
þ T Cells in HTLV-I-
Infected Patients
Patient Foxp3
(% CD4
þCD25
þ)
a
HTLV-I (Tax) Proviral Load
(Copies/100 cells)
b
HAM-1 16.60 50.22
HAM-2 23.40 22.45
HAM-3 21.60 23.09
HAM-4 21.40 86.61
HAM-5 24.30 19.41
HAM-6 16.80 20.98
HAM-7 6.20 29.92
HAM-8 18.40 24.78
AC-1 45.80 1.69
AC-2 46.20 0.02
AC-3 18.80 3.10
AC-4 54.10 3.55
AC-5 28.10 12.43
AC-6 45.50 0.48
AC-7 19.50 14.28
AC-8 57.80 2.48
Means 6 SD and significance of values of Foxp3
þCD4
þCD25
þ percentages were: HAM
cells, 18.59 6 5.77; AC cells, 43.23 6 12.95; p ¼ 0.0033 (Mann-Whitney U test). Means 6
SD and significance of proviral load values were: HAM loads, 34.68 6 23.19; AC loads, 4.75
6 5.47; p ¼ 0.0008 (Mann-Whitney U test).
aFoxp3
þCD4
þCD25
þ cells were quantitated by flow cytometric analysis as described
previously [34].
bHTLV-I proviral load was determined by quantitative real-time PCR (TaqMan) as
described previously [47].
AC, HTLV-I-infected asymptomatic carrier; HAM, HTLV-I-associated myelopathy; SD,
standard deviation.
DOI: 10.1371/journal.ppat.0020033.t001
Figure 5. Foxp3 Inhibits the Expression of HTLV-I Tax Directed from an
Infectious Molecular Clone
HEK 293T cells (5 3 10
5) were seeded into six-well plates 1 d prior to
transfection in the absence or presence of an HTLV-I infectious molecular
clone (pACH; 800 ng) and either a control (EGFP), Foxp3, or DFKH
expression vector (800 ng). Expression of HTLV-I Tax from the molecular
clone was measured by quantitative RT-PCR (TaqMan).
DOI: 10.1371/journal.ppat.0020033.g005
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Foxp3 Suppresses NF-jB and CREB Pathwayssteps. To determine whether Foxp3 can disrupt the function/
recruitment of the coactivator protein p300, we introduced a
Gal4 reporter vector and a Gal4-BD-CREB-1 expression
vector into HEK 293T cells in the absence or presence of
Foxp3, p300, and/or control expression vectors (Figure 7C).
As expected, p300 overexpression stimulated transcription of
the Gal4-BD-CREB-1 fusion protein. Foxp3, again, repressed
basal levels of Gal4-BD-CREB-1 activation by more than 2-
fold, while effectively neutralizing Gal4-BD-CREB-1 activa-
tion in the presence of p300. We next analyzed the effect of
Foxp3 on phosphorylation of CREB at serine 133 in
forskolin-treated HEK 293T cells by Western blot analysis.
Overexpression of Foxp3 failed to reduce the detectable
levels of CREB phosphorylation using a phosphospeciﬁc
antibody for CREB-1 (unpublished data). However, when we
attempted to determine whether Foxp3 could physically
interact with the coactivator protein p300, we found that
p300 immunoprecipitated Foxp3 when both proteins were
overexpressed in HEK 293T cells (Figure 7D). Collectively,
these results suggest that Foxp3 antagonizes CREB-depend-
ent gene expression by directly interacting with coactivator
p300 and interfering with its function and/or recruitment to
CREB-responsive promoter sequences.
Discussion
In the present study, we show that Foxp3 functions as a
potent repressor of NF-jB- and CREB-dependent transcrip-
tional activation. Furthermore, the carboxyl-terminal FKH
domain appears to be dispensable for mediating these effects,
at least in T cell populations. This observation may become
important in light of recent reports suggesting that Foxp3
expression in thymic epithelial cells was crucial for directing
development of T cells in the thymus [42]. Interestingly, the
Figure 6. Foxp3 Inhibits CREB-Dependent Transcription
(A) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with a CREB or an HTLV-I LTR luciferase reporter vector (200 ng) in
the presence or absence of a Foxp3, DFKH, or control expression vector (500 ng) and internal reference plasmid (pGL4-TKhRluc2; 50 ng).
(B) Purified CD4
þT cells (2310
6) from two healthy donors were transfected with a CREB luciferase reporter vector (2,000 ng) in the presence or absence
of a Foxp3, DFKH, or control expression vector (2,000 ng) and internal reference plasmid (pGL4-TKhRluc2; 1,000 ng).
(C) Purified CD4
þ T cells (2 3 10
6) from healthy donors were transfected with an HTLV-I LTR luciferase reporter vector (2,000 ng) in the presence or
absence of a Foxp3, DFKH, or control expression vector (2,000 ng) and internal reference plasmid (pGL4-TKhRluc2; 1,000 ng).
(D) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with a Gal4 luciferase reporter vector (200 ng) in the presence or
absence of Gal4-BD, Gal4-BD-CREB-1, or Gal4-BD-c-Jun (500 ng) along with Foxp3 or control expression vector (500 ng) and internal reference plasmid
(pGL4-TKhRluc2; 50 ng). Cells from A, B, C, and D were harvested at 24 h posttransfection and analyzed for luciferase activity. Relative luciferase activity
was normalized to the internal reference control.
(E) Foxp3, DFKH, and CREB-1 expression in whole-cell extracts (20 lg) derived from HEK 293T cells transfected with a control expression vector (EGFP),
Foxp3, or DFKH expression vectors were analyzed by Western blot analysis. b-actin expression was analyzed as a loading control.
DOI: 10.1371/journal.ppat.0020033.g006
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Foxp3 Suppresses NF-jB and CREB Pathwaysmajority of the genetic mutations associated with IPEX, a
severe autoimmune disorder caused by functional inactiva-
tion of Foxp3, map to the carboxyl-terminal FKH domain or
the leucine zipper domain in the central region of the
protein. Only one mutation associated with IPEX to date has
been mapped to the amino-terminal proline-rich region [43].
It is possible that the FKH domain has a complex tertiary
structure that is particularly sensitive to misfolding caused by
genetic mutations and that an intact FKH domain is
absolutely critical for promoting Foxp3 function in the
nucleus, whereas the structure of the amino-terminal proline-
rich region may tolerate certain mutations as long as the NF-
jB/NF-AT binding motif remains unaltered. This motif may
also include the zinc ﬁnger domain. A logical region that may
be targeted by the amino-terminal proline-rich region of
Foxp3 is the Rel homology domain found in both NF-jB and
NF-AT family proteins. A region that may also be important
with respect to Foxp3 function is the leucine zipper domain,
as demonstrated by the number of mutations associated with
IPEX that have been mapped in this region of Foxp3. The
role of this domain in Foxp3 function remains uncharac-
terized, but may play a role in dimer formation as it does in
other Foxp family members [44].
Because the pathogenesis of a number of retroviral-
induced immunologic disorders such as HIV-1/AIDS and
HTLV-I/HAM/TSP have been associated with dysregulation of
Foxp3 expression [8,45], we also examined the role of Foxp3
in retroviral gene expression. HIV-1 LTR activation in CD4
þ
T cells is critically dependent on two tandem NF-jB sites
located between nucleotide positions 102 and 81 within the
HIV-1 enhancer region, whereas HTLV-I LTR activation in
the presence or absence of the HTLV-I-encoded trans-
activator protein Tax is independent of NF-jB [18]. To our
knowledge for the ﬁrst time, Foxp3 was shown to have a
direct effect on HIV-1 LTR transcription. Deletion of the NF-
jB sites within the HIV-1 enhancer region reduced the
responsiveness of the HIV-1 LTR to Foxp3-mediated sup-
pression. In addition, the FKH domain of Foxp3 was required
for this inhibitory effect in HEK 293T cells, but not in Jurkat
T cells, similar to Foxp3-mediated suppression of a synthetic
NF-jB reporter. The direct effect of Foxp3 down-regulating
HIV-1 gene expression correlates well with recently reported
evidence indicating that higher regulatory activity of
Figure 7. Foxp3 Antagonizes CREB Activation by Blocking Recruitment of Coactivator Protein p300
(A and B) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with a CREB or an HTLV-I LTR luciferase reporter vector (200
ng) in the presence or absence of a Foxp3, DFKH, or control expression vector (500 ng) and internal reference plasmid (pGL4-TKhRluc2; 50 ng). Forskolin
(10 lM) was added to the appropriate reactions 20 h posttransfection. Reactions were assayed 24 h posttransfection for luciferase activity (A) and CREB-
1 and ATF-2 DNA-binding activity (B).
(C) HEK 293T cells (5310
5) were seeded into six-well plates 1 d prior to transfection with a Gal4 luciferase reporter vector (200 ng) in the presence or
absence of Gal4-BD-CREB-1 (500 ng) along with a control, Foxp3, or p300 expression vector (500 ng) and internal reference plasmid (pGL4-TKhRluc2; 50
ng). Cells were harvested at 24 h posttransfection and analyzed for luciferase activity. Relative luciferase activity in (A and C) was normalized to the
internal reference control.
(D) Whole-cell extracts from HEK 293T cells transfected with a control (EGFP) or Foxp3 expression vector together with a p300-HA expression vector
were immunoprecipitated with anti-HA monoclonal antibody. Proteins were then separated by SDS-PAGE and immunoblotted with anti-Foxp3
(ab10563) to detect immunoprecipitates and with anti-HA for the lysates.
DOI: 10.1371/journal.ppat.0020033.g007
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Foxp3 Suppresses NF-jB and CREB PathwaysCD4
þCD25
þ T cells from HIV-1-infected patients was
associated with lower HIV-1 viral loads in these patients [46].
Foxp3 also affected two well-known functions of HTLV-I
Tax: transactivation of the NF-jB pathway and, most
surprisingly, transactivation of the HTLV-I LTR. Trans-
activation of the HTLV-I LTR by Tax involves the interaction
of ATF/CREB factors with Tax in the nucleus. Binding of Tax
enhances ATF/CREB dimerization and promotes assembly of
Tax-ATF/CREB complexes onto speciﬁc sequences in the
viral promoter known as Tax-responsive elements. This series
of steps allows Tax to recruit coactivator proteins CBP/p300
to the viral promoter and facilitate a high level of viral gene
expression [24–26]. Transactivation of the NF-jB pathway by
Tax was inhibited by overexpression of full-length Foxp3, but
not DFKH, as seen with basal activation of the HIV-1 LTR and
a synthetic NF-jB reporter in HEK 293T cells. However, Tax-
mediated transactivation of the HTLV-I LTR was inhibited by
overexpression of both full-length Foxp3 as well as DFKH in
both HEK 293T cells and CD4
þ T cells. We demonstrated that
Foxp3 did not directly affect the functioning of Tax, but
rather Foxp3 targeted the transcription factors required for
Tax transactivation (i.e., NF-jB and a then-unknown cellular
factor, which we identiﬁed in this study as CREB). The
negative effect of Foxp3 on HTLV-I gene expression was
conﬁrmed utilizing an HTLV-I infectious molecular clone.
Importantly, we demonstrated that HTLV-I-infected indi-
viduals with the highest levels of Foxp3 protein expression
within the CD4
þCD25
þ T cells population exhibited lower
proviral loads than did individuals with the lowest levels of
Foxp3 protein expression. Previous studies have demonstra-
ted that the HTLV-I proviral load directly correlates with
HTLV-I Tax mRNA load, the frequency of immunopatho-
genic virus-speciﬁc CD8
þ T cells, and disease severity in
patients with HAM/TSP [47]. These results have important
implications on the utility of Foxp3 in controlling viral gene
expression and thus pathogenesis of HAM/TSP. Therefore,
Foxp3 becomes an attractive target for the development of
novel therapeutic applications directed at modulating the
expression of this important regulatory protein, especially in
light of recent observations that the expression of Foxp3 can
also be down-regulated by HTLV-I Tax [8].
As the activation of the HTLV-I LTR depends primarily on
ATF/CREB proteins (whether in the presence or the absence
of Tax), we investigated whether Foxp3 could interact with
this additional cellular signaling pathway. While the DNA-
binding activity of CREB is, in most cases, constitutive, the
transactivation potential of CREB is regulated by the
phosphorylation of CREB and recruitment of CBP/p300
[48]. Our data demonstrate that Foxp3 interferes with the
latter of these two processes and that the recruitment of the
coactivator protein p300, and resulting transcriptional
activation are blocked by Foxp3. This may be the result of
the physical interaction we detected between Foxp3 and
p300. With respect to HTLV-I LTR activity, while full-length
Foxp3 inhibited both basal and Tax-dependent transcription
by ;50%, DFKH appeared less effective in suppressing basal
activation (;25% inhibition) compared to Tax-dependent
activation (;50% inhibition). The effect of DFKH on basal
activation of the HTLV-I LTR in HEK 293T cells was very
s i m i l a rt ot h a ts h o w nf o ras y n t h e t i cC R E Br e p o r t e r ,
suggesting that the FKH domain of Foxp3 is important at
some level. As observed with NF-jB activation, the Foxp3
mutant lacking the FKH domain was a stronger inhibitor of
CREB activation in CD4
þ T cells than in HEK 293T epithelial
cells. Therefore, it appears that in CD4
þ T cells, the FKH
domain is dispensable for the proper functioning of Foxp3
with respect to both NF-jB and CREB activation.
In summary, this is, to our knowledge, the ﬁrst direct
evidence implicating a role for the Treg-speciﬁc transcrip-
tion factor Foxp3 in regulating retroviral gene expression. In
addition, we identify the CREB pathway as a molecular target
of Foxp3. Since CREB has been shown to regulate multiple
genes involved in transcription (e.g., JunD, c-Fos, signal
transducer of activated T cells 3 [STAT3]), cell cycle (e.g.,
p15
INK4b, cyclin A, cyclin D1), and immune regulation (e.g.,
IL-2, IL-6, T-cell receptor a) (reviewed in [48]), the ﬁndings
presented in this report broaden the potential range of
signaling pathways under the control of the regulatory
protein Foxp3. Our evidence stresses the importance of
Foxp3 expression and Treg function in the development and
maintenance of protective immunity against HIV-1 and
HTLV-I. Based on recent ﬁndings, Foxp3 may limit HIV-1
and HTLV-I transcription by interfering with activation of
NF-jB and CREB pathways. However, observing that this
inhibitory effect is not absolute, a low level of viral gene
expression may persist in CD4
þ T cells (in particular
regulatory T cells, which are known reservoirs of HIV-1 and
HTLV-I) and result in the accumulation of viral proteins that
either stimulate NF-jB and/or CREB activation or directly
inhibit Foxp3 expression or function. The imbalance of NF-
jB and CREB activation caused by these viral gene products
may be a crucial step in the pathogenesis of virus-induced
immunological disorders such as AIDS and HAM/TSP. Future
studies will be directed at identifying and characterizing
cellular proteins that interact with Foxp3 both in the nucleus
and cytoplasm, in order to better address how Foxp3
functions to guide the development and function of
regulatory T cells in health and disease.
Materials and Methods
Cell culture. HEK 293T cells were cultured in Dulbecco’s modiﬁed
Eagle medium (Invitrogen, Carlsbad, California, United States). Jurkat
T cells and primary human CD4
þ T cells were cultured in RPMI-1640
medium (Invitrogen). Media were supplemented with 2 mM L-
glutamine, 100 U/ml penicillin, 100 lg/ml streptomycin (Cambrex,
East Rutherford, New Jersey, United States), and 10% fetal bovine
serum (Atlanta Biologicals, Norcross, Georgia, United States).
Patients and cell preparation. PBMCs were prepared by centrifu-
gation over Ficoll-Hypaque gradients (BioWhittaker, Walkersville,
Maryland, United States) from eight HAM/TSP patients and eight
ACs, and the cells were viably cryopreserved in liquid nitrogen until
tested. HAM/TSP was diagnosed according to WHO guidelines [49].
HTLV-I seropositivity was determined by ELISA (Abbott Laborato-
ries, Abbott Park, Illinois, United States), with conﬁrmation by
Western blot analysis (Genelabs Technologies, Redwood City,
California, United States). Blood samples were obtained after
informed consent as part of a clinical protocol reviewed and
approved by the NIH institutional review panel.
Plasmids. Expression vectors encoding human Foxp3 (pCMV-
Foxp3-IRES-EGFP) and human Foxp3 lacking the forkhead (FKH)
domain (pCMV-DFKH-IRES-EGFP) were generous gifts from S.
Ziegler (Benaroya Research Institute). pEGFP-C2 was provided by I.
Lipinski (NIDDK/NIH). pcDNA3 was provided by K. T. Jeang (NIAID/
NIH). pCMV4-Tax was a generous gift from W. Greene (University of
California San Francisco). pGL4-luc2 and pGL4-TKhRluc2 were
purchased from Promega (Madison, Wisconsin, United States).
pUC18 was purchased from Stratagene (La Jolla, California, United
States). HIV-1 wt LTR and HIV-1 D-jB LTR luciferase reporter
vectors were constructed by cloning the XhoI/HindIII LTR fragments
from pHIV-CAT and pD-jB-HIV-CAT (AIDS Research and Reference
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pGL4-luc2. NF-jB, HTLV-I LTR, and CREB luciferase reporter and
pCMV-p300-HA expression vectors were generously provided by B.
Wigdahl (Drexel University College of Medicine). HTLV-I pACH
infectious molecular clone has been described previously [30]. pFR-
luc, pFA-CMV, pFA2-CREB-1, and pFA2-c-Jun were purchased from
Stratagene. pFA-Tax (encoding a fusion protein consisting of the
Gal4 DNA-binding domain fused in-frame to HTLV-I Tax) was
constructed by PCR ampliﬁcation of HTLV-I Tax using pCMV4-Tax
as a template and BamHI/BglII-tagged primers. The ampliﬁed insert
was digested and ligated into the BamHI/BglII sites of pFA-CMV.
Plasmid contents were conﬁrmed by DNA sequencing.
Isolation of primary human CD4þ T cells. CD4þ T cells were
isolated from cryopreserved healthy donor PBMCs by negative
selection with the CD4
þ T Cell Isolation Kit II (Miltenyi Biotech,
Bergisch Gladbach, Germany) according to manufacturer’s guide-
lines. Purity of negatively selected CD4
þ T cells was consistently
higher than 96% as determined by ﬂow cytometry.
Transient expression and luciferase assays. HEK 293T cells were
plated at a density of 5 3 10
5 cells/well in six-well culture plates (BD
Biosciences, San Diego, California, United States) 1 d prior to
transfection with the appropriate plasmid DNA (;2 lg total) using
FuGene 6 transfection reagent (Roche, Basel, Switzerland). Jurkat T
cells were plated at 1310
6 cells/well in six-well culture plates the day
of transfection with the appropriate plasmid DNA (;2 lg total) using
FuGene 6 transfection reagent. Primary human CD4þT cells (23106)
were nucleofected with the speciﬁed plasmid DNA (5 lg total) using
the Human T Cell Nucleofection Kit (Amaxa, Gaithersburg, Mary-
land, United States). Forskolin (10 lM; Calbiochem, San Diego,
California, United States) was added in some experiments 20 h
posttransfection. Cells were harvested 24 h posttransfection and
luciferase activity was analyzed using the Dual-luciferase Reporter
Assay System (Promega) and a Monolight 2010 luminometer
(Analytical Luminescence Laboratory, San Diego, California, United
States) according to manufacturer’s guidelines. pGL4-TKhRluc2 was
used as an internal control to normalize for transfection efﬁciency.
Nucleofected CD4
þ T cells were also monitored for transfection
efﬁciency and cell viability 24 h posttransfection as follows. Trans-
fection efﬁciency was routinely ;30% as determined by ﬂow
cytometric analysis of EGFP expression. Cell viability, determined
by staining with 7-amino-actinomycin D (7-AAD; BD Biosciences),
was routinely ;70%. Both transfection efﬁciency and cell viability in
nucleofected CD4
þ T cells was independent of the plasmids used.
Foxp3 and HTLV-I Tax expression analysis by real-time RT-PCR.
Real-time RT-PCR analysis of Foxp3 and HTLV-I Tax expression was
performed as previously described [8,47]. Brieﬂy, total RNA was
extracted using the RNeasy Mini Kit (Qiagen, Valencia, California,
United States) according to manufacturer’s guidelines, and cDNA was
synthesized by reverse transcription using TaqMan Gold RT-PCR Kit
using random hexamer primers (Applied Biosystems, Foster City,
California, United States). Foxp3 and HTLV-I Tax mRNA expression
was quantiﬁed by real-time PCR using ABI PRISM 7700 Sequence
Detection System (Applied Biosystems). The normalized values in
each sample were calculated as the relative quantity of Foxp3 or
HTLV-I Tax mRNA expression divided by the relative quantity of
HPRT mRNA expression. The values were calculated by the following
formula: normalized Foxp3 or HTLV-I Tax expression ¼ 2Ct value of
HPRT – Ct value of Foxp3 or HTLV-I Tax.
Real-time PCR. Real-time PCR analysis of HTLV-I (Tax) proviral
load was performed as previously described [47,50]. DNA was
extracted from 1 3 10
6 cells using Puregene DNA Isolation Kit
(Gentra, Minneapolis, Minnesota, United States), and 100 ng of the
sample DNA solution was analyzed by this system. The HTLV-I
proviral DNA load was calculated by the following formula: copy
number of HTLV-I (pX) per 100 cells ¼ (copy number of pX)/(copy
number of b-actin/2) 3 100.
Western blot analysis. HEK 293T cells were plated at a density of 5
310
5 cells/well in six-well culture plates (BD Biosciences) 1 d prior to
transfection with the appropriate plasmid DNA (2 lg total) using
FuGene 6 transfection reagent (Roche). Cells were harvested 24 h
posttransfection for whole-cell lysates in RIPA buffer (50 mM Tris-
HCl [pH 7.4], 150 mM NaCl, 1% Igepal (NP-40), 0.5% sodium
deoxycholate, 1 mM EDTA, 1 mM DTT, 1 mM PMSF, and 13
Complete Mini Protease Inhibitor [Roche]). Protein concentration
was determined by Lowry assay (Bio-Rad, Hercules, California,
United States) and colorimetric reactions were read using a VersaMax
microplate reader (Molecular Devices, Sunnyvale, California, United
States) at an absorbance of 750 nm. Size fractionation was performed
on 20 lg of protein/sample by SDS-PAGE, and the protein was
transferred to nitrocellulose or PVDF membranes and subjected to
immunoblotting using the indicated antibodies. Foxp3 was detected
using rabbit anti-human Foxp3 polyclonal antibody (ab4728 or
ab10563; Abcam, Cambridge, United Kingdom) and anti-rabbit IgG-
HRP secondary antibody (Cell Signaling Technology, Beverly,
Massachusetts, United States). NF-jB p65 and CREB-1 were detected
using rabbit anti-human polyclonal (p65) or monoclonal antibody
(CREB-1; 48H2) (Cell Signaling Technology). Beta-actin was detected
using a mouse monoclonal antibody (AC-15; Sigma, St. Louis,
Missouri, United States). For coimmunoprecipitation analysis, cell
lysates were precleared with 30 ll of protein A/G plus-agarose beads
(Santa Cruz Biotechnology, Santa Cruz, California, United States) and
then incubated with mouse monoclonal anti-HA antibody (6E2; 1:100;
Cell Signaling Technology) and 30 ll of protein A/G plus-agarose
beads overnight. The immunoprecipitates were washed four times
with RIPA buffer, resuspended in SDS sample buffer, and heated at
95 8C for 5 min. Proteins were then treated as described for Western
blot analysis.
Transcription factor DNA-binding analysis (TF-ELISA). CREB-1
and ATF-2 DNA-binding activity was analyzed with the TransFactor
Proﬁling (Inﬂammation 1) Kit (BD Biosciences) according to the
manufacturer’s protocol. Nuclear extracts were prepared from HEK
293T cells transfected with a control vector (EGFP) or Foxp3
expression vector (1,000 ng) in the presence or absence of forskolin
(10 lM for 4 h) using the TransFactor Extraction Kit (BD Biosciences).
Protein concentration was determined using a Biophotometer
(Eppendorf, Hamburg, Germany). Nuclear extracts (20 lg) were
incubated in preblocked wells containing plate-bound double-
stranded oligonucleotides corresponding to an ATF/CREB consensus
sequence (...TGACATCA...). Wells were washed, incubated with the
appropriate primary antibody, washed, incubated with secondary
antibody (HRP-labeled), washed again, and ﬁnally developed with
TMB substrate. Colorimetric reactions were read using a VersaMax
microplate reader (Molecular Devices) at an absorbance of 655 nm.
Flow cytometric analysis of Foxp3 protein expression. Cryopre-
served PBMCs from HAM/TSP patients or HTLV-I-infected ACs were
thawed and washed with FACS buffer (13PBS, 0.1% NaN3, 5% FBS).
Cells (1.5 3 10
6) were ﬁxed by sequential formaldehyde/methanol
ﬁxation as follows. Cells were carefully resuspended in FACS buffer
and ﬁxed with 100 ll of reagent A (Fix & Perm kit; Caltag
Laboratories, Burlingame, California, United States) at room temper-
ature for 3 min followed by 2 ml of 70% methanol for 5 min at 4 8C.
Cells were washed twice and permeabilized with 100 ll of reagent B
(Fix & Perm kit) and stained for intracellular Foxp3 with mouse anti-
human Foxp3 monoclonal antibody (0.5 lg of ab22510; Abcam) or the
appropriate isotype control for 30 min. Cells were washed twice and
s t a i n e dw i t hC y 5 - c o n j u g a t e dg o a ta n t i - m o u s ei m m u n o g l o b u l i n
F(ab9)2 secondary antibody (Caltag Laboratories) for an additional
30 min. Cells were washed twice and stained for surface CD4
expression with PE-labeled anti-CD4 (BD) and CD25 expression with
FITC-labeled anti-CD25 (BD). Cells were washed twice and analyzed
on a FACSCalibur (BD). Data analysis was performed using FlowJo
(Tree Star, Ashland, Oregon, United States).
Statistical analyses. The Mann-Whitney U test was used to compare
the data between patients with HAM/TSP and AC.
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